The specific overexpression of MYC in the Basal/SCC-like subtype combined with activity in its closest corresponding subtypes of breast- and lung cancer may warrant pre-clinical testing of this agent in Basal/SCC-like bladder cancer. This evidence concerns the gene MYC and urinary bladder carcinoma.